Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2004
04/01/2004US20040063634 Modified kertinocyte growth factor (kgf) with reduced immunogenicity
04/01/2004US20040063628 Active agent delivery systems and methods for protecting and administering active agents
04/01/2004US20040063615 For therapy of diabetes
04/01/2004US20040063611 Comprising levothyroxine sodium, gelatine and fillers, which is free of organic solvent residues
04/01/2004US20040063187 Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatography
04/01/2004US20040063140 Methods for diagnosis of cancer using erbB-3
04/01/2004US20040062855 Edible PGA coating composition
04/01/2004US20040062843 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent
04/01/2004US20040062813 Transdermal drug delivery devices having coated microprotrusions
04/01/2004US20040062812 Drug in mixture of matrix forming polymer and ion exchange resin
04/01/2004US20040062810 Removal blockage in blood vessels; mixture of angiogenesis inhibitor and polymer
04/01/2004US20040062808 Agent delivery system capable of selectively releasing an agent
04/01/2004US20040062805 Pregelatinized starch in a controlled release formulation
04/01/2004US20040062804 Multilayer; active materials, core, shell
04/01/2004US20040062800 Compressed matrix tablet; mixture of drug and swellable polymer; side effect reduction
04/01/2004US20040062796 Enteric administering; anticancer, antiulcer agents; drug with bioadhesive ligand
04/01/2004US20040062793 Protein network; wound healing agent
04/01/2004US20040062779 Fine particle sizes; mixture of ascoric acid in stabilization, anhydrous vehicle; transdermal penetration
04/01/2004US20040062773 Compositions for the delivery of antigens
04/01/2004US20040062761 Nucleic acid and corresponding protein entitled 151P3D4 useful in treatment and detection of cancer
04/01/2004US20040062749 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
04/01/2004US20040062748 Complex of active material and polyoxyethylene glycol
04/01/2004US20040062746 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
04/01/2004US20040062743 Mixture with film forming polymer
04/01/2004US20040062733 Subunguicide, and method for treating onychomycosis
04/01/2004US20040062724 Thin, flexible, multilayer film; applying, adhesion to teeth; supplying active materials
04/01/2004US20040062719 Carrier for drug delivery; crystal structure core with surface coating; induce crystallization of amorphous particles; hermetic sealed packages
04/01/2004US20040062718 Particles for inhalation having sustained release properties
04/01/2004DE10244657A1 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products
04/01/2004DE10244282A1 Zubereitung mit antioxidanten Eigenschaften Composition having antioxidant properties
04/01/2004DE10243365A1 Composition containing propoxylated and ethoxylated alkanol, useful as surfactant in e.g. cleaning compositions and pharmaceuticals, has low free alcohol content
04/01/2004CA2535769A1 Polymer-linker-drug conjugates for targeted drug delivery
04/01/2004CA2499900A1 Dri nasal sprays
04/01/2004CA2499681A1 Drug delivery
04/01/2004CA2499321A1 Obtaining and use of therapeutic antibodies entering into the cell
04/01/2004CA2499093A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
04/01/2004CA2498331A1 Formulation for lipophilic agents
04/01/2004CA2443463A1 Concentrate of a factor viii:c-containing von willebrand factor and the process relating thereto
03/2004
03/31/2004EP1402913A1 Dry powder inhalation system for transpulmonary administration
03/31/2004EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence
03/31/2004EP1402901A1 Test kit for intracellular introduction of protein and/or peptide and method of intracellular introduction
03/31/2004EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
03/31/2004EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases
03/31/2004EP1402882A1 Acid-containing tooth desensitising material
03/31/2004EP1402786A1 Ximenynic acid
03/31/2004EP1402256A2 P-cadherin as a target for anti-cancer therapy
03/31/2004EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS
03/31/2004EP1402015A2 A soluble complex comprising a retroviral surface glycoprotein
03/31/2004EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof
03/31/2004EP1401875A1 Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
03/31/2004EP1401818A2 Targeted multivalent macromolecules
03/31/2004EP1401567A1 Unimolecular polymeric micelles with an ionizable inner core
03/31/2004EP1401504A1 Uv-screening peptide-flavonoid conjugates
03/31/2004EP1401503A1 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
03/31/2004EP1401502A1 Pharmaceutical formulation
03/31/2004EP1401501A1 Oral pharmaceutical compositions with modified release of the active ingredient
03/31/2004EP1401500A1 Nucleotide compounds that block the bitter taste of oral compositions
03/31/2004EP1401480A2 Use of endostatin in the treatment of ocular neovascularization
03/31/2004EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds
03/31/2004EP1401473A2 Transporters comprising spaced arginine moieties
03/31/2004EP1401467A1 Alpha-fetoprotein peptides and uses thereof
03/31/2004EP1401466A1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue
03/31/2004EP1401442A1 S-omeprazole (esomeprazole inclusion complex with cyclodextrins
03/31/2004EP1401435A1 Topical application of thiazolyl amides
03/31/2004EP1401430A1 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
03/31/2004EP1401423A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
03/31/2004EP1401420A2 Perturbed membrane-binding compounds
03/31/2004EP1401409A2 Stable powder inhalation dosage formulation
03/31/2004EP1401406A2 Delivery of a bioactive material
03/31/2004EP1401405A1 Oral pharmaceutical compositions with improved bioavailability
03/31/2004EP1401404A2 Method of encapsulating an active substance
03/31/2004EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
03/31/2004EP1401400A1 Porous matrix comprising cross-linked particles
03/31/2004EP1401399A2 Pharmaceutical compositions containing polymer and drug assemblies
03/31/2004EP1401398A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF
03/31/2004EP1401397A2 Pharmaceutical formulation having a masked taste and method for the production thereof
03/31/2004EP1401396A2 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
03/31/2004EP1401377A2 Methods for treating cancer
03/31/2004EP1401376A2 Colloidal metal compositions and methods
03/31/2004EP1401374A1 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
03/31/2004EP1401294A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols
03/31/2004EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof
03/31/2004EP1305010B1 Dosage forms for treatment of oral mycoses
03/31/2004EP1282393A4 External application for enhancing the skin permeability of the active components therein
03/31/2004EP1250156A4 Method for nucleic acid transfection of cells
03/31/2004EP1230338A4 Continuous-flow method for preparing microparticles
03/31/2004EP1220685B1 Pharmaceutical compositions of fibrinolytic agent
03/31/2004EP1218026B1 Preparation of a medicament to enhance healing of the sternum after sternotomy
03/31/2004EP1171132B1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
03/31/2004EP1165053B1 Fast-dispersing dosage forms containing fish gelatin
03/31/2004EP1124543A4 Controlled release formulation for water soluble drugs
03/31/2004EP1109526B1 Improved stability for injection solutions
03/31/2004EP1073438B1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDINE)-5H-BENZO (5,6) CYCLOHEPTA (1,2-b) PYRIDINE ORAL COMPOSITIONS
03/31/2004EP1053020B1 Absorbable microparticles
03/31/2004EP1012256B1 Recombinant fusion proteins based on ribosome-inactivating proteins of european mistletoe viscum album
03/31/2004EP0975367B1 Improved delivery of drugs to mucosal surfaces
03/31/2004EP0873130B1 Compositions comprising pvp having an average molecular weight in the range of 7.000 to 12.000 daltons
03/31/2004EP0858343B1 Continuous low-dose cytokine infusion therapy
03/31/2004EP0858323B1 Process to manufacture implants containing leuprolide
03/31/2004EP0809498B1 Pharmaceuitical composition for topical application containing acyclovir and hydrocortisone